Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers

NCT04941287 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04941287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04941287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 15, 2021
Completion date
April 29, 2026
Enrollment
57 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic distal bile duct adenocarcinoma, metastatic gallbladder carcinoma, metastatic intrahepatic cholangiocarcinoma, recurrent distal bile duct adenocarcinoma, recurrent gallbladder carcinoma, recurrent intrahepatic cholangiocarcinoma, stage iv distal bile duct cancer ajcc v8, stage iv gallbladder cancer ajcc v8, stage iv intrahepatic cholangiocarcinoma ajcc v8, unresectable liver carcinoma